Differential characteristics in polypathological inpatients in internal medicine departments and acute geriatric units: the PLUPAR study.

Aim: To determine whether there are any differences between polypathological patients attended in Internal Medicine departments and acute Geriatric units.

Methods: A cross-sectional multicenter study was performed. Polypathological patients admitted to an internal medicine or geriatrics department and attended by investigators consecutively between March 1 and June 30, 2011 were included.

[Darunavir in patients with advanced HIV and multiresistance. The POWER, DUET and BENCHMRK studies].

Darunavir is a new protease inhibitor. This drug is highly active against wild-type and multiresistant HIV strains, binds strongly to the HIV-1 protease, has extremely high affinity for the protease and, when enhanced by subtherapeutic doses of ritonavir, has a favorable resistance profile differing from that of current protease inhibitors (PIs). After determining the optimal dose, phase IIb clinical trials (POWER studies 1 and 2) observed much higher virological and immunological efficacy with darunavir than with the comparator PIs.